Assembly Biosciences Files 2024 10-K, Cites Gilead Deal
Ticker: ASMB · Form: 10-K · Filed: 2025-03-20T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, pharmaceuticals, partnership, equity-agreement
TL;DR
ASMB 2024 10-K out. Mentions microbiome deal & Gilead equity. Check financials.
AI Summary
Assembly Biosciences, Inc. filed its 2024 10-K on March 20, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Ventrus Biosciences Inc., is focused on pharmaceutical preparations. Key events and agreements mentioned include a microbiome purchase agreement and at-the-market offerings in 2024, as well as equity agreements with Gilead Sciences, Inc.
Why It Matters
This filing provides investors with a comprehensive overview of Assembly Biosciences' financial health, strategic activities, and potential risks for the 2024 fiscal year, including significant partnerships.
Risk Assessment
Risk Level: medium — The company operates in the pharmaceutical sector, which is inherently high-risk due to R&D costs, regulatory hurdles, and market competition.
Key Numbers
- 2834 — SIC Code (Indicates the company operates in Pharmaceutical Preparations)
Key Players & Entities
- Assembly Biosciences, Inc. (company) — Filer of the 10-K
- Ventrus Biosciences Inc. (company) — Former name of Assembly Biosciences
- Gilead Sciences, Inc. (company) — Party to equity agreements
- 2024-12-31 (date) — Fiscal year end
- 20250320 (date) — Filing date
FAQ
What were the key financial results for Assembly Biosciences in fiscal year 2024?
The provided text is an excerpt from the 10-K header and does not contain specific financial results for fiscal year 2024. A full review of the filing document is required for this information.
What is the nature of the 'microbiome purchase agreement' mentioned?
The filing indicates 'asmb:MicrobiomePurchaseAgreementMember' as a relevant item for the period 2024-01-01 to 2024-12-31, but the specific terms and details of the agreement are not provided in this excerpt.
What are the 'at-the-market offerings' that occurred in 2024?
The filing references 'asmb:TwoThousandAndTwentyFourAtTheMarketOfferingsMember' for the period 2024-01-01 to 2024-12-31. Further details on the volume and proceeds of these offerings would be in the full filing.
What is the significance of the equity agreements with Gilead Sciences, Inc.?
The filing lists 'asmb:EquityAgreementsMember' involving 'asmb:GileadSciencesIncorporatedMember' and 'us-gaap:CommonStockMember'. The specific details and implications of these agreements are not elaborated in this excerpt.
When did Assembly Biosciences change its name from Ventrus Biosciences Inc.?
The filing states the 'DATE OF NAME CHANGE' from 'VENTRUS BIOSCIENCES INC' to 'ASSEMBLY BIOSCIENCES, INC.' was '20080211'.
From the Filing
0000950170-25-042673.txt : 20250320 0000950170-25-042673.hdr.sgml : 20250320 20250320161531 ACCESSION NUMBER: 0000950170-25-042673 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 89 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250320 DATE AS OF CHANGE: 20250320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35005 FILM NUMBER: 25756625 BUSINESS ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 10-K 1 asmb-20241231.htm 10-K 10-K 0001426800 false FY http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202307Member http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember .1429 .0588 .0833 .0833 .0833 0.0833 1 http://fasb.org/srt/2024#ChiefExecutiveOfficerMember 0001426800 asmb:RegulatoryMember asmb:MicrobiomePurchaseAgreementMember 2024-01-01 2024-12-31 0001426800 asmb:TwoThousandEighteenEmployeeStockPurchasePlanMember 2024-11-01 2024-11-30 0001426800 asmb:TwoThousandAndTwentyFourAtTheMarketOfferingsMember 2024-01-01 2024-12-31 0001426800 us-gaap:CommonStockMember asmb:GileadSciencesIncorporatedMember asmb:EquityAgreementsMember us-gaap:PrivatePlacementMember srt:MaximumMember 2024-12-01 2024-12-31 0001426800 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001426800 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 asmb:TwoThousandAndTwentyAtTheMarketOfferingsMember 2023-01-01 2023-12-31 0001426800 2024-10-01 2024-12-31 0001426800 us-gaap:CommonStockMember asmb:GileadSciencesIncorporatedMember asmb:EquityAgreementsMember 2024-12-31 0001426800 us-gaap:EmployeeStockOptionMember 2023-12-31 0001426800 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001426800 us-gaap:WarrantMember asmb:RegisteredDirectOfferingMember srt:MaximumMember 2024-06-01 2024-06-30 0001426800 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001426800 asmb:GileadSciencesIncorporatedMember asmb:OptionLicenseAndCollaborationAgreementMember 2023-10-01 2023-10-31 0001426800 asmb:BeiGeneAgreementMember 2024-01-01 2024-12-31 0001426800 asmb:BeiGeneLimitedMember 2023-01-01 2023-12-31 0001426800 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember asmb:EmployeesIncludingExecutiveOfficersMember 2023-01-01 2023-12-31 0001426800 asmb:RegisteredDirectOfferingAndPrivatePlacementMember 2024-12-31 0001426800 asmb:TwoThousandEighteenEmployeeStockPurchasePlanMember 2024-01-01 2024-12-31 0001426800 us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001426800 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:CommonStockMember asmb:GileadSciencesIncorporatedMember asmb:EquityAgreementsMember us-gaap:PrivatePlacementMember 2024-12-31 0001426800 us-gaap:CashEquivalentsMember 2024-12-31 0001426800 asmb:TwoThousandAndTwentyAtTheMarketOfferingsMember srt:MaximumMember 2020-08-31 0001426800 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001426800 us-g